PL3137595T3 - Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania - Google Patents

Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania

Info

Publication number
PL3137595T3
PL3137595T3 PL15739327T PL15739327T PL3137595T3 PL 3137595 T3 PL3137595 T3 PL 3137595T3 PL 15739327 T PL15739327 T PL 15739327T PL 15739327 T PL15739327 T PL 15739327T PL 3137595 T3 PL3137595 T3 PL 3137595T3
Authority
PL
Poland
Prior art keywords
polypeptide
interest
methods
vertebrate cells
recombinantly expressing
Prior art date
Application number
PL15739327T
Other languages
English (en)
Inventor
Holger Laux
Sandrine Romand
Ursula Bodendorf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53682742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3137595(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3137595T3 publication Critical patent/PL3137595T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21109Matriptase (3.4.21.109)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N2015/1006Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
PL15739327T 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania PL3137595T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461985589P 2014-04-29 2014-04-29
US201461994310P 2014-05-16 2014-05-16
PCT/IB2015/053110 WO2015166427A2 (en) 2014-04-29 2015-04-29 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP15739327.3A EP3137595B1 (en) 2014-04-29 2015-04-29 Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest

Publications (1)

Publication Number Publication Date
PL3137595T3 true PL3137595T3 (pl) 2019-09-30

Family

ID=53682742

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15739327T PL3137595T3 (pl) 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania
PL19161388.4T PL3536776T3 (pl) 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19161388.4T PL3536776T3 (pl) 2014-04-29 2015-04-29 Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania

Country Status (17)

Country Link
US (2) US11512335B2 (pl)
EP (3) EP4332231A3 (pl)
JP (1) JP6636453B2 (pl)
KR (1) KR102307278B1 (pl)
CN (1) CN106255749A (pl)
AU (1) AU2015254913B2 (pl)
CA (1) CA2947198C (pl)
DK (2) DK3536776T5 (pl)
ES (2) ES2968879T3 (pl)
IL (1) IL248184B (pl)
LT (2) LT3137595T (pl)
MX (1) MX368664B (pl)
PL (2) PL3137595T3 (pl)
PT (2) PT3137595T (pl)
RU (1) RU2710726C2 (pl)
SG (1) SG11201608358VA (pl)
WO (1) WO2015166427A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
AU2018290281B2 (en) 2017-06-22 2021-12-16 Vertex Pharmaceuticals Incorporated Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
WO2020081328A1 (en) * 2018-10-15 2020-04-23 The Regents Of The University Of California Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins
PE20221416A1 (es) 2019-09-18 2022-09-20 Novartis Ag Proteinas de fusion nkg2d y sus usos
US20210244821A1 (en) 2020-02-05 2021-08-12 Novartis Ag Cho cell expressed het il-15
EP4150085A1 (en) * 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
CN115551519A (zh) * 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
EP4526462A1 (en) * 2022-05-19 2025-03-26 Novartis AG Improved protein production using mirna technology

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
AU572108B2 (en) 1983-01-19 1988-05-05 Genentech Inc. Human tpa production using vectors coding for dhfr protein
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU2001278488A1 (en) 2000-07-25 2002-02-05 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
CN100513414C (zh) * 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
MXPA05003493A (es) * 2002-10-02 2005-09-30 Catalyst Biosciences Metodos para generar y seleccionar proteasas con especificidad alterada.
ATE399872T1 (de) 2003-03-11 2008-07-15 Serono Lab Expressionvektoren, die den promotor des ie2-gens des maus cytomegalovirus enthalten
CN102443627B (zh) * 2004-08-10 2014-10-29 加的夫生物学有限公司 用于乳腺癌的预后的试剂盒
ATE504602T1 (de) 2004-12-20 2011-04-15 Amgen Fremont Inc Für humane matriptase spezifische bindungsproteine
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
ES2546086T3 (es) 2007-12-21 2015-09-18 Novartis Ag Sistema de selección en un cultivo de células eucariotas basado en un gen receptor de folato unido a la membrana
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
CA2753814C (en) 2009-02-27 2018-07-31 Novartis Ag Novel selection vectors and methods of selecting eukaryotic host cells
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
PT2563904E (pt) 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
ES2676412T3 (es) 2011-06-02 2018-07-19 Socpra Sciences Santé Et Humaines S.E.C. Inhibidores de matriptasa y usos de los mismos contra infecciones por ortomixovirus
CN110078827A (zh) * 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
SG11201408554QA (en) * 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
EP4332231A3 (en) 2014-04-29 2024-05-29 Novartis AG Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Also Published As

Publication number Publication date
EP3137595B1 (en) 2019-03-13
ES2968879T3 (es) 2024-05-14
CN106255749A (zh) 2016-12-21
IL248184B (en) 2021-03-25
IL248184A0 (en) 2016-11-30
EP3536776A1 (en) 2019-09-11
AU2015254913A1 (en) 2016-10-27
DK3536776T3 (da) 2024-01-15
JP6636453B2 (ja) 2020-01-29
DK3137595T3 (da) 2019-06-17
EP4332231A3 (en) 2024-05-29
PL3536776T3 (pl) 2024-03-25
MX368664B (es) 2019-10-10
LT3137595T (lt) 2019-06-25
WO2015166427A2 (en) 2015-11-05
BR112016024534A2 (pt) 2017-10-10
AU2015254913B2 (en) 2018-05-17
RU2016145928A (ru) 2018-05-29
KR20160147919A (ko) 2016-12-23
RU2016145928A3 (pl) 2018-12-26
PT3137595T (pt) 2019-06-19
JP2017514484A (ja) 2017-06-08
EP4332231A2 (en) 2024-03-06
DK3536776T5 (da) 2024-09-02
CA2947198A1 (en) 2015-11-05
US20170044587A1 (en) 2017-02-16
SG11201608358VA (en) 2016-11-29
RU2710726C2 (ru) 2020-01-10
LT3536776T (lt) 2024-01-25
WO2015166427A3 (en) 2016-01-14
MX2016014222A (es) 2017-05-04
US11512335B2 (en) 2022-11-29
US20230323419A1 (en) 2023-10-12
ES2731246T3 (es) 2019-11-14
EP3137595A2 (en) 2017-03-08
PT3536776T (pt) 2024-01-12
EP3536776B1 (en) 2023-10-25
KR102307278B1 (ko) 2021-09-30
CA2947198C (en) 2023-01-17

Similar Documents

Publication Publication Date Title
IL275307B (en) Syntac polypeptides and their uses
IL248184A0 (en) Novel invertebrate cells and methods for recombinant expression of a desired polypeptide
PT3149025T (pt) Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
IL248361A0 (en) Recombinant host cell for expression of desired proteins
EP3240799A4 (en) S-alkylated hepcidin peptides and methods of making and using thereof
IL245854A0 (en) New eukaryotic cells and methods for recombinant expression of the desired product
EP3268477A4 (en) Structure based methods for modification of pip-72 polypeptides and pip-72 polypeptides derived therefrom
IL251799A0 (en) Serpin-fused polypeptides and methods of using them
IL245856B (en) New eukaryotic cells and methods for recombinant expression of the desired product
EP3092248A4 (en) Fusion polypeptides and methods of use
IL246642A0 (en) Materials and methods for quantifying pld-1 protein levels
GB201410031D0 (en) Polypeptides and uses thereof
IL250178A0 (en) Methods and preparations for the expression of peptides in the cell
GB2527908B (en) Closure means and method of use thereof
IL247448A0 (en) Peptides and methods of use
PL2957516T3 (pl) Pojemnik i sposób jego produkcji
GB201401549D0 (en) Cover means and method of use thereof